OPKO Health, Inc. Stock Split Ratio
OPKO Health, Inc. (OPK) reported Stock Split Ratio of 1.00% for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-27.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2023-02-27
- OPKO Health, Inc. stockholders' equity note, stock split, conversion ratio for fiscal 2020 was 1.00%, a 0.00% change from fiscal 2019.
- OPKO Health, Inc. stockholders' equity note, stock split, conversion ratio for fiscal 2019 was 1.00%, a 0.00% change from fiscal 2018.
- OPKO Health, Inc. stockholders' equity note, stock split, conversion ratio for fiscal 2018 was 1.00%, a 87.95% decline from fiscal 2017.
- OPKO Health, Inc. stockholders' equity note, stock split, conversion ratio for fiscal 2017 was 8.30%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month as first filed |
|---|---|---|
| 2020-12-31 | 1.00% 10-K · filed 2023-02-27 | |
| 2019-12-31 | 1.00% 10-K · filed 2022-03-01 | |
| 2018-12-31 | 1.00% 10-K · filed 2021-02-18 | |
| 2017-12-31 | 8.30% 10-K · filed 2020-03-02 | 8.33% 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |